ACT 462206

Drug Profile

ACT 462206

Alternative Names: ACT-462206

Latest Information Update: 18 Oct 2013

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 19 Jul 2012 Discontinued - Phase-I for Insomnia (in volunteers) in Switzerland (PO)
  • 31 Jan 2012 Actelion Pharmaceuticals completes a phase I trial in Insomnia (in volunteers) in Netherlands (NCT01954589)
  • 30 Nov 2011 Phase-I clinical trials in Insomnia (in volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top